Skip navigation
Pay Bill Portals

Signatera™ Designed on Genome:

Ultrasensitive ctDNA detection from the leaders in MRD testing

Learn More

Why Signatera™ Designed on Genome?

  • Ultra-sensitive detection down to 1 part per million (PPM)1

  • Increased lead times and enhanced sensitivity to detect recurrence1

  • Backed by Signatera™ experience in >1M samples1

Signatera™’s mPCR-NGS approach

Sequences deeper on the most critical variants, providing the most personalized and clinically meaningful MRD signal

  • Ultra-deep sequencing (up to 350,000x coverage for each selected variant)1

  • Highly curated selection of 64 clonal variants for optimized balance of ultra-sensitivity and high specificity1

  • Proprietary variant selection and calling algorithms for bespoke MRD monitoring1

alt text

Natera has the most comprehensive portfolio on MRD solutions to support patient care

Signatera™
Most extensively validated, adopted, and reimbursed MRD assay available
Signatera™ Designed on Genome
Lower limit of detection (LoD) for enhanced sensitivity and increased lead time to recurrence1
Tissue Free MRD
(available in 2025)
Epigenomic assay with fast turnaround time for when tissue is not available

Same Signatera™ report; same sample requirements

  • Patient report: contains the same look and feel as existing Signatera™ report
  • Results will be identified as Signatera™ Genome
  • TAT: For initial result (4 weeks); 7-10 day TAT for subsequent results
*Can only be ordered for new patients (unable to convert existing orders)

Set up a meeting with our medical science liaisons

Learn More
  • Signatera™ has the same sample requirements whether designed on genome or exome
  • Collect samples as usual and include the printed requisition in the kit

Signatera™ is the most extensively validated and widely adopted MRD assay

Widely Used by Clinicans

>1 million
Signatera™ tests ordered by EOY 20241
>300,000
Signatera™ patients1
>40%
of oncologists1

Extensive and Robust Clinical Evidence

>100
publications1
>260
congress presentations & posters1
>20
clinical studies prospectively using Signatera™1

Is Signatera™ Designed on Genome, right for you?

We’re here to help you find out

Natera would like to send you information about our products and services. You may unsubscribe from these communications at any time. By submitting your information you are agreeing to Natera's terms of use and privacy policy.

References

1Natera data on file.

icon-angle icon-bars icon-times